Association Between the Number of Comorbidities and the Risk of a Serious Infection in Rheumatoid Arthritis Treated by a First Biologic Agent

J Clin Rheumatol. 2022 Jan 1;28(1):e270-e273. doi: 10.1097/RHU.0000000000001618.

Authors

Christopher Banse, Estelle Houivet¹, Aurélien Loison², Rémi Varin², Sophie Pouplin³, Thierry Lequerré³, Olivier Vittecoq³

Affiliations

¹ Unit of Biostatistics.
² Department of Pharmacy, Rouen University Hospital, Rouen, France.
³ From the Department of Rheumatology, CIC/CRB 1404, Rouen University Hospital, Normandie Univ, Rouen.

PMID: 33337817
DOI: 10.1097/RHU.0000000000001618

No abstract available

MeSH terms

Antirheumatic Agents* / adverse effects
Arthritis, Rheumatoid* / diagnosis
Arthritis, Rheumatoid* / drug therapy
Arthritis, Rheumatoid* / epidemiology
Biological Factors
Biological Products* / adverse effects
Comorbidity
Humans

Substances

Antirheumatic Agents
Biological Factors
Biological Products